BioCentury | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

...bevacizumab (PF-06439535) Trazimera, biosimilar trastuzumab, trastuzumab (PF-05280014) Avastin, bevacizumab (RG435, Anti-VEGF antibody, R435) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Herceptin...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...RG597) Avastin, bevacizumab (RG435, Anti-VEGF antibody, R435) G-Lasta, Neulasta, Peglasta, pegfilgrastim (KRN125, SD/01) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Remicade...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

...undoubtedly be adjustments,” Rind told BioCentury. Erin McCallister, Senior Editor Humira, adalimumab (D2E7) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Revlimid...
BioCentury | Aug 23, 2019
Clinical News

Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

...run study. Sandi Wong and Hongjiang Li, Staff Writers AR201 biosimilar rituximab (ABP 798) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Aimmune...
BioCentury | Aug 22, 2019
Distillery Techniques

Delivering mAbs to CNS metastases using polymer-based nanoparticles

...syuchen@mednet.ucla.edu CONTACT: Masakazu Kamata, same affiliation as above email: masa3k@ucla.edu Claire Quang MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) University...
BioCentury | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

...kinase 2 BioCentury Staff Darzalex, daratumumab (JNJ-54767414, humax-cd38) Doptelet, avatrombopag (AKR-501, E5501) Gardasil 9 (V503) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) NanoFlu Soliris...
BioCentury | Jun 13, 2019
Company News

June 12 Company Quick Takes: Macao approves Zai's Zejula; plus Roche, NIH, CVS and Dassault-Medidata

...acquisition in 4Q19. Paul Bonanos, Associate Editor, and Hongjiang Li, Staff Writer MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Zejula...
BioCentury | Mar 22, 2019
Company News

Roche gets European approval of rituximab to treat skin disease

...CD20 antigen in the EU as MabThera. Elizabeth S. Eaton, Staff Writer MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Biogen...
BioCentury | Feb 22, 2019
Politics, Policy & Law

Azar’s IPI: socialist or capitalist?

...Compound #), rhuFab V2 (Former compound #), ranibizumab (Generic), Lucentis (Informal) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Amgen...
BioCentury | Feb 1, 2019
Politics, Policy & Law

Trading blows over trade secrets

...S. Eaton, Staff Writer Avastin, bevacizumab (RG435, Anti-VEGF antibody, R435) Herceptin, trastuzumab (RG597) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Pulmozyme...
Items per page:
1 - 10 of 3732
BioCentury | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

...bevacizumab (PF-06439535) Trazimera, biosimilar trastuzumab, trastuzumab (PF-05280014) Avastin, bevacizumab (RG435, Anti-VEGF antibody, R435) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Herceptin...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...RG597) Avastin, bevacizumab (RG435, Anti-VEGF antibody, R435) G-Lasta, Neulasta, Peglasta, pegfilgrastim (KRN125, SD/01) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Remicade...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

...undoubtedly be adjustments,” Rind told BioCentury. Erin McCallister, Senior Editor Humira, adalimumab (D2E7) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Revlimid...
BioCentury | Aug 23, 2019
Clinical News

Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

...run study. Sandi Wong and Hongjiang Li, Staff Writers AR201 biosimilar rituximab (ABP 798) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Aimmune...
BioCentury | Aug 22, 2019
Distillery Techniques

Delivering mAbs to CNS metastases using polymer-based nanoparticles

...syuchen@mednet.ucla.edu CONTACT: Masakazu Kamata, same affiliation as above email: masa3k@ucla.edu Claire Quang MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) University...
BioCentury | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

...kinase 2 BioCentury Staff Darzalex, daratumumab (JNJ-54767414, humax-cd38) Doptelet, avatrombopag (AKR-501, E5501) Gardasil 9 (V503) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) NanoFlu Soliris...
BioCentury | Jun 13, 2019
Company News

June 12 Company Quick Takes: Macao approves Zai's Zejula; plus Roche, NIH, CVS and Dassault-Medidata

...acquisition in 4Q19. Paul Bonanos, Associate Editor, and Hongjiang Li, Staff Writer MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Zejula...
BioCentury | Mar 22, 2019
Company News

Roche gets European approval of rituximab to treat skin disease

...CD20 antigen in the EU as MabThera. Elizabeth S. Eaton, Staff Writer MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Biogen...
BioCentury | Feb 22, 2019
Politics, Policy & Law

Azar’s IPI: socialist or capitalist?

...Compound #), rhuFab V2 (Former compound #), ranibizumab (Generic), Lucentis (Informal) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Amgen...
BioCentury | Feb 1, 2019
Politics, Policy & Law

Trading blows over trade secrets

...S. Eaton, Staff Writer Avastin, bevacizumab (RG435, Anti-VEGF antibody, R435) Herceptin, trastuzumab (RG597) MabThera, Rituxan, rituximab (R105, RG105, IDEC-C2B8) Pulmozyme...
Items per page:
1 - 10 of 3732